Current and Future Disease Progression of the Chronic HCV Population in the United States

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zalesak, Martin ^a   Francis, Kevin ^a   Gedeon, Alex ^a   Gillis, John ^a   Hvidsten, Kyle ^b   Kidder, Phyllis ^b   Li, Hong ^a   Martyn, Derek ^a   Orne, Leslie ^a   Smith, Amanda ^a   Kwong, Ann ^b,c  

^a Trinity Partners LLC   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c InnovaTID   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BABY BOOMER; COST OF ILLNESS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; FORECASTING; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; POPULATION GROWTH; PREVALENCE; UNITED STATES;

AGED; COHORT STUDIES; COSTS AND COST ANALYSIS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; UNITED STATES;

EID: 84877958027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063959     Document Type: Article

References (52)

1. Williams I, (1999) Epidemiology of hepatitis C in the United States. Am J Med 107: 2-9.
2. McHutchison JG, Bacon BR, Owens GS, (2007) Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care. 13: 327-336.
3. McHutchison JG, Bacon BR, (2005) Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 11: 286-295.
4. Centers for Disease Control and Prevention. Viral Hepatitis Statistics and Surveillance. 2009. Available: http://www.cdc.gov/hepatitis/Statistics/index.htm. Accessed 2009 February 8.
5. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, et al. (2009) HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 9: 34.
6. Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, et al. (2011) Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant 11: 1188-1200.
7. Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C, (2010) Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 8: 924-933.
8. Alter MJ, (1997) Epidemiology of hepatitis C. Hepatology. 26: 62S-65S.
9. Kim WR, (2002) The burden of hepatitis C in the United States. Hepatology 36: 30-34.
10. Chak E, Talal AH, Sherman KE, Schiff ER, Saad S, (2011) Hepatitis C virus infection in USA: An estimate of true prevalence. Liver Int 31: 1090-1101.
11. Neal KR, (2007) Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 56: 1098-1104.
12. Ly KN, Xing J, Klevens M, Jiles RB, Ward JW, et al. (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Int Med 156: 271-278.
13. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH, (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 132: 296-305.
14. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trépo C, (2007) Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 27: 335-339.
15. Schuppan D, Afdhal NH, (2008) Liver cirrhosis. Lancet 371: 838-851.
16. Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, et al. (2012) Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol 17: 5007-5013.
17. Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, et al. (2011) Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 54: 418-424.
18. Drumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, et al. (2011) Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol 55: 45-52.
19. Nasta P, (2011) "Immune activation, aging and gender" and progression of liver disease. Acta Biomed 82: 115-123.
20. Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, et al. (2010) HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 17: 400-409.
21. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, et al. (2009) Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 51: 655-666.
22. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trepo C, (2007) Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 27: 335-339.
23. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, et al. (2010) Liver transplantation in the United States, 1999-2008. Am J Transplant 10: 1003-1019.
24. Dorfman JD, Schulick R, Choti MA, Geschwind JH, Kamel I, et al. (2007) Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol 13: 781-784.
25. Leigh JP, Bowlus CL, Leistikow BN, Schenker S, (2001) Cost of hepatitis C. Arch Intern Med. 161: 2231-2237.
26. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V, (2011) Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 45: 17-24.
27. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD, (2012) New protease inhibitors for the treatment of chronic hepatitis C. Ann Int Med. 156: 279-290.
28. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, et al. (2012) The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Int Med 156: 263-270.
29. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, et al. (2012) Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 55: 1344-1355.
30. Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS (2012) Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Pub Health doi: 10.2105/AJPH.2011.300488. Accessed August 23 2012.
31. Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, et al. (2011) Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 31Suppl. 2: 4-17.
32. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW, (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: 513-521.
33. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB, (2007) Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 14: 107-115.
34. Davis GL, Albright JE, Cook SF, Rosenberg DM, (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331-338.
35. Wong JB, McQuillan GM, McHutchison JG, Poynard T, (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90: 1562-1569.
36. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS, (2000) The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31: 777-782.
37. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: Questionnaires, Datasets and Related Documentation. November 2011. Available: http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed 2011 August 15.
38. Department of Health and Human Services. Who is eligible for Medicare? June 2001. Available: https://questions.medicare.gov/app/answers/detail/a_id/10/~/who-is-eligible-for-medicare%3F. Accessed 2011 December 11.
39. US Census Bureau. The 2012 Statistical Abstract: The National Data Book. July 2012. Available: http://www.census.gov/compendia/statab/cats/births_deaths_marriages_divorces/deaths.html. Accessed 2013 January 11.
40. Center for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed 2013 March 18.
41. US Census Bureau. Population Estimates: National Intercensal Estimates (2000-2009). December 2011. Available: http://www.census.gov/popest/data/intercensal/national/nat2010.html. Accessed 2011 December 3.
42. Centers for Medicare and Medicaid Services. National Health Expenditure Data: Historical. January 2012. Available: http://www.cms.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage. Accessed 2012 February 11.
43. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556-562.
44. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Int Med 144: 705-714.
45. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM, (2012) The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 12: 86-96.
46. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
47. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, et al. (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 9: 509-516.
48. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, et al. (2012) Association between sustained virologic response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-2593.
49. Shepherd J, Brodin HF, Cave CB, Waugh NR, Price A, et al. (2005) Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 21: 47-54.
50. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, et al. (2004) Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 99: 1490-1496.
51. Center for Disease Control, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Available http://www.cdc.gov/nchhstp/newsroom/2012/HCV-Testing-Recs-PressRelease.html. Accessed 2012 August 23.
52. Center for Disease Control, Morbidity and Mortality Weekly Report, August 17, 2012. "Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965".